Oppenheimer Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $33.00

Tyra Biosciences (NASDAQ:TYRA) had its target price increased by Oppenheimer from $25.00 to $33.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s price objective suggests a potential upside of 35.47% from the company’s previous close.

Other equities research analysts also recently issued reports about the stock. Piper Sandler started coverage on shares of Tyra Biosciences in a research report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Thursday, August 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $26.40.

Tyra Biosciences Trading Up 1.5 %

NASDAQ TYRA opened at $24.36 on Thursday. Tyra Biosciences has a 1-year low of $10.38 and a 1-year high of $25.14. The company has a 50 day moving average of $21.29 and a 200-day moving average of $18.73. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -14.50 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. On average, equities research analysts forecast that Tyra Biosciences will post -1.53 earnings per share for the current year.

Insider Activity at Tyra Biosciences

In other Tyra Biosciences news, CEO Todd Harris sold 5,698 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $24.31, for a total transaction of $138,518.38. Following the sale, the chief executive officer now owns 1,496,729 shares of the company’s stock, valued at $36,385,481.99. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 15.40% of the stock is currently owned by insiders.

Institutional Trading of Tyra Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. grew its stake in shares of Tyra Biosciences by 43.9% during the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after buying an additional 3,180,155 shares during the last quarter. BVF Inc. IL grew its stake in shares of Tyra Biosciences by 70.1% during the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after buying an additional 1,921,599 shares during the last quarter. Perceptive Advisors LLC grew its stake in shares of Tyra Biosciences by 50.5% during the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock worth $16,108,000 after buying an additional 338,208 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after buying an additional 140,833 shares during the last quarter. Finally, Kynam Capital Management LP grew its stake in shares of Tyra Biosciences by 51.4% in the first quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after purchasing an additional 175,000 shares during the last quarter. Institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.